Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia D Suerth

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Viruses|December 10, 2014
Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapyJulia D Suerth, Verena Labenski, Axel Schambach
Current Opinion in Immunology|September 22, 2012
Genetic modification of lymphocytes by retrovirus-based vectorsJulia D Suerth, Axel Schambach, Christopher Baum
Journal of Virology|April 23, 2010
Self-inactivating alpharetroviral vectors with a split-packaging designJulia D Suerth, Tobias Maetzig, Melanie Galla, et al.
Current Gene Therapy|May 13, 2015
RETRACTED: Novel and safer self-inactivating vectors for gene therapy of Wiskott-Aldrich SyndromeEmanuele G. Coci, Tobias Maetzig, Daniela Zychlinski, et al.
Human Gene Therapy Methods|February 7, 2013
Evaluating a ligation-mediated PCR and pyrosequencing method for the detection of clonal contribution in polyclonal retrovirally transduced samplesMartijn H Brugman, Julia D Suerth, Michael Rothe, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 25, 2015
Efficient generation of gene-modified human natural killer cells via alpharetroviral vectorsJulia D Suerth, Michael A Morgan, Stephan Kloess, et al.
Frontiers in Pharmacology|March 3, 2015
Advantages and applications of CAR-expressing natural killer cellsWolfgang Glienke, Ruth Esser, Christoph Priesner, et al.
Biomaterials|May 11, 2016
Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytesVerena Labenski, Julia D Suerth, Elke Barczak, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 18, 2014
Modified lentiviral LTRs allow Flp recombinase-mediated cassette exchange and in vivo tracing of "factor-free" induced pluripotent stem cellsJohannes Kuehle, Soeren Turan, Tobias Cantz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 5, 2012
Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicingKerstin B Kaufmann, Christian Brendel, Julia D Suerth, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Viruses|December 10, 2014
Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapyJulia D Suerth, Verena Labenski, Axel Schambach
Current Opinion in Immunology|September 22, 2012
Genetic modification of lymphocytes by retrovirus-based vectorsJulia D Suerth, Axel Schambach, Christopher Baum
Journal of Virology|April 23, 2010
Self-inactivating alpharetroviral vectors with a split-packaging designJulia D Suerth, Tobias Maetzig, Melanie Galla, et al.
Current Gene Therapy|May 13, 2015
RETRACTED: Novel and safer self-inactivating vectors for gene therapy of Wiskott-Aldrich SyndromeEmanuele G. Coci, Tobias Maetzig, Daniela Zychlinski, et al.
Human Gene Therapy Methods|February 7, 2013
Evaluating a ligation-mediated PCR and pyrosequencing method for the detection of clonal contribution in polyclonal retrovirally transduced samplesMartijn H Brugman, Julia D Suerth, Michael Rothe, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 25, 2015
Efficient generation of gene-modified human natural killer cells via alpharetroviral vectorsJulia D Suerth, Michael A Morgan, Stephan Kloess, et al.
Frontiers in Pharmacology|March 3, 2015
Advantages and applications of CAR-expressing natural killer cellsWolfgang Glienke, Ruth Esser, Christoph Priesner, et al.
Biomaterials|May 11, 2016
Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytesVerena Labenski, Julia D Suerth, Elke Barczak, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 18, 2014
Modified lentiviral LTRs allow Flp recombinase-mediated cassette exchange and in vivo tracing of "factor-free" induced pluripotent stem cellsJohannes Kuehle, Soeren Turan, Tobias Cantz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 5, 2012
Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicingKerstin B Kaufmann, Christian Brendel, Julia D Suerth, et al.
Pageof 2